uncovered that in breast cancer, FBXW7 deletion activates CCL2 promoter by reducing NOTCH turnover, which recruits monocytic myeloid-derived suppressor cells (Mo-MDSCs) and TAMs to the premetastatic niche and accelerates tumor metastasis and immunosuppression [115, 116]. Here, CCL2 is linked to breast cancer.